D'Alessandro Giuseppe, Bianco Maria Rosaria, Politis Spiridion, Ferrandina Celestino, Rossi Giuseppe, Altomare Emanuele
II Medicina Interna Universitaria, Azienda Ospedaliero Universitaria Ospedali Riuniti, 71100 Foggia.
Reumatismo. 2006 Jan-Mar;58(1):59-61.
Anti TNF-alpha drugs seem to be the new frontier of Rheumatoid Arthritis (RA) therapy. The association infliximab methotrexate has been approved for the treatment of RA not responding to the classic therapy, but the short clinical experience in using antiTNF-alpha molecules brings to segnalation of new risks or adverse events. We describe a case of a patient, treated for many years with classic RA therapy, which developed a refractory anemia after treatment with association infliximab-methotrexate.
抗肿瘤坏死因子-α药物似乎是类风湿性关节炎（RA）治疗的新前沿。英夫利昔单抗与甲氨蝶呤联合用药已被批准用于治疗对传统疗法无反应的类风湿性关节炎，但使用抗肿瘤坏死因子-α分子的临床经验尚短，已发现了新的风险或不良事件。我们描述了一例患者，该患者接受传统类风湿性关节炎治疗多年，在接受英夫利昔单抗-甲氨蝶呤联合治疗后出现难治性贫血。
